G. Konecny

1.2k total citations
18 papers, 936 citations indexed

About

G. Konecny is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Konecny has authored 18 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Konecny's work include HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). G. Konecny is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). G. Konecny collaborates with scholars based in Germany, United States and Ireland. G. Konecny's co-authors include Mark D. Pegram, Dennis J. Slamon, Malgorzata Beryt, Christopher J. O’Callaghan, Richard J. Pietras, DJ Slamon, Michael Untch, Steffen Kahlert, M. J. Duffy and John Crown and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

G. Konecny

17 papers receiving 904 citations

Peers

G. Konecny
K. Aogi Japan
CL Arteaga United States
Guorong Yang China
Vivian Ng United States
Lorenza Pistola Italy
Daniela Kandioler-Eckersberger Austria
B. Lisboa Germany
Naixin Liang China
Ulla Kasten-Pisula Germany
Giuseppe Gullo Ireland
K. Aogi Japan
G. Konecny
Citations per year, relative to G. Konecny G. Konecny (= 1×) peers K. Aogi

Countries citing papers authored by G. Konecny

Since Specialization
Citations

This map shows the geographic impact of G. Konecny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Konecny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Konecny more than expected).

Fields of papers citing papers by G. Konecny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Konecny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Konecny. The network helps show where G. Konecny may publish in the future.

Co-authorship network of co-authors of G. Konecny

This figure shows the co-authorship network connecting the top 25 collaborators of G. Konecny. A scholar is included among the top collaborators of G. Konecny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Konecny. G. Konecny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Konecny, G., Andrea E. Wahner Hendrickson, Boris Winterhoff, et al.. (2024). 721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors. Annals of Oncology. 35. S551–S551. 2 indexed citations
3.
Konecny, G., Andrea E. Wahner Hendrickson, Boris Winterhoff, et al.. (2023). 756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23. Annals of Oncology. 34. S517–S517. 5 indexed citations
4.
Minckwitz, G von, M. Kaufmann, Sherko Kümmel, et al.. (2011). PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy.. Cancer Research. 71(24_Supplement). PD07–5. 1 indexed citations
5.
Minckwitz, Gϋnter von, M. Kaufmann, Sherko Küemmel, et al.. (2011). Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.. Journal of Clinical Oncology. 29(15_suppl). 1028–1028. 46 indexed citations
6.
Loibl, Sibylle, G von Minckwitz, Jens‐Uwe Blohmer, et al.. (2011). S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab.. Cancer Research. 71(24_Supplement). S5–4. 18 indexed citations
7.
8.
Ryan, Bríd M., G. Konecny, Steffen Kahlert, et al.. (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Annals of Oncology. 17(4). 597–604. 130 indexed citations
9.
Stemmler, Hans‐Joachim, Christoph Salat, Horst Lindhofer, et al.. (2005). Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.. PubMed. 25(4). 3047–54. 15 indexed citations
10.
Konecny, G., Hans‐Joachim Lück, Michael Untch, et al.. (2004). HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 96(15). 1141–1151. 110 indexed citations
11.
Pegram, Mark D., G. Konecny, Christopher J. O’Callaghan, et al.. (2004). Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 739–749. 395 indexed citations
12.
Untch, Michael, et al.. (2001). Dose-dense and sequential strategies in adjuvant breast cancer therapy.. PubMed. 15(5 Suppl 7). 14–20. 4 indexed citations
13.
Pegram, Mark D., et al.. (2000). Trastuzumab and chemotherapeutics: drug interactions and synergies.. PubMed. 27(6 Suppl 11). 21–5; discussion 92. 155 indexed citations
14.
Konecny, G., et al.. (2000). HER-2/neu als prädiktiver Faktor beim Mammakarzinom. Geburtshilfe und Frauenheilkunde. 60(12). 609–619. 1 indexed citations
15.
Thomssen, Christoph, Michael Untch, G. Konecny, et al.. (1998). Lack of correlation betweenc-erbB-2 overexpression and the effect of dose-intensification of adjuvant chemotherapy in high-risk breast cancer patients. European Journal of Cancer. 34. S30–S30. 4 indexed citations
16.
Thomssen, Christoph, Michael Untch, H. Kühnle, et al.. (1997). Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.. PubMed. 24(1 Suppl 3). S13–6. 5 indexed citations
17.
Lück, Hans‐Joachim, Christoph Thomssen, Andreas duBois, et al.. (1996). Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.. PubMed. 23(1 Suppl 1). 33–6. 21 indexed citations
18.
Fröhlich, Dieter, G. Konecny, F. W. Schildberg, et al.. (1994). Local serum application: restoration of sufficient host defense in human peritonitis. European Journal of Clinical Investigation. 24(1). 28–35. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Aogi Breakdown of academic impact, for papers by CL Arteaga Breakdown of academic impact, for papers by Guorong Yang Breakdown of academic impact, for papers by Vivian Ng Breakdown of academic impact, for papers by Lorenza Pistola Breakdown of academic impact, for papers by Daniela Kandioler-Eckersberger Breakdown of academic impact, for papers by B. Lisboa Breakdown of academic impact, for papers by Naixin Liang Breakdown of academic impact, for papers by Ulla Kasten-Pisula Breakdown of academic impact, for papers by Giuseppe Gullo
Rankless by CCL
2026